- Trial Phase
- Approved
- Time to Market
- Already approved. However, Indivior discontinued all marketing and promotion of OPVEE in September 2025 after a settlement with the New York Attorney General over misleading sales tactics. The drug is effectively off the commercial market.
- Why 3/10
- No upcoming catalyst for OPVEE specifically: it is already FDA-approved but Indivior discontinued marketing in September 2025 after a legal settlement, making it effectively a dead product. Indivior's stock is driven by SUBLOCADE (its lead opioid-use-disorder treatment, Q3 2026 net revenue up 22% to $267M) and the pending merger with Supernus Pharmaceuticals closing November 2, 2026. OPVEE contributed less than 4% of total revenue and is not moving the stock.
OPVEE by itself has no catalysts left to watch. For INDV stock, the near-term events are the Supernus merger closing (expected November 2, 2026), after which the combined company will trade under ticker SUPN. The merger makes OPVEE's commercial failure even less relevant, as the combined entity will have a diversified CNS pipeline beyond opioid-use-disorder products.
Price Chart
Executive Summary
OPVEE (nalmefene) is an FDA-approved opioid-overdose reversal nasal spray that Indivior launched in 2023 as a longer-acting alternative to Narcan (naloxone). The drug was a commercial failure: harm reduction groups rejected it over safety and pricing concerns, and Indivior halted all marketing in September 2025 after settling a New York Attorney General investigation into misleading promotion. Today, OPVEE is effectively off the market and contributed less than 4% of Indivior's revenue. Indivior's stock is now driven by its lead product SUBLOCADE and the pending merger with Supernus Pharmaceuticals (expected to close November 2, 2026).
How It Works
OPVEE is an opioid antagonist nasal spray that rapidly reverses an opioid overdose by knocking the opioids off their receptors in the brain and blocking them. It is similar to naloxone (Narcan) but is designed to last longer in the body, which the company argued could be an advantage against long-lasting synthetic opioids like fentanyl. It is a rescue medicine, not a treatment for addiction.
Trial Status
OPVEE was approved by the FDA on May 22, 2023, based on safety and pharmacokinetic studies in healthy subjects, not a traditional efficacy trial (the FDA allows opioid-overdose reversal drugs to be approved based on showing rapid opioid-reversal effect in controlled settings). After launch, the drug generated meager sales and faced strong opposition from harm reduction groups who argued it was no more effective than naloxone (Narcan), more expensive, and carried additional withdrawal risks.
The Two-Sided Case
Upcoming Catalysts
- No upcoming catalysts for OPVEE specifically: marketing has been discontinued and there are no pending regulatory actions or clinical trials for this drug.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Indivior Pharmaceuticals Inc. PRESS-RELEASE INDV ·Originating report